<SEC-DOCUMENT>0001193125-24-225549.txt : 20240925
<SEC-HEADER>0001193125-24-225549.hdr.sgml : 20240925
<ACCEPTANCE-DATETIME>20240925110525
ACCESSION NUMBER:		0001193125-24-225549
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20240925
FILED AS OF DATE:		20240925
DATE AS OF CHANGE:		20240925

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Theratechnologies Inc.
		CENTRAL INDEX KEY:			0001512717
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A8
		FISCAL YEAR END:			1130

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35203
		FILM NUMBER:		241321998

	BUSINESS ADDRESS:	
		STREET 1:		2015 PEEL STREET
		STREET 2:		5TH FLOOR
		CITY:			MONTREAL
		STATE:			A8
		ZIP:			H3A 1T8
		BUSINESS PHONE:		514-336-7800

	MAIL ADDRESS:	
		STREET 1:		2015 PEEL STREET
		STREET 2:		5TH FLOOR
		CITY:			MONTREAL
		STATE:			A8
		ZIP:			H3A 1T8
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d868442d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C.&nbsp;20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Report of
Foreign Private Issuer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Rule <FONT STYLE="white-space:nowrap">13a-16</FONT> or
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>under the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>September&nbsp;25, 2024 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">001-35203</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>THERATECHNOLOGIES INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2015 Peel
Street, Suite 1100 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Montr&eacute;al, Qu&eacute;bec, Canada </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>H3A 1T8 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of
principal executive offices) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form
<FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F:</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
<FONT STYLE="white-space:nowrap">20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form</FONT> <FONT STYLE="white-space:nowrap">40-F&#8194;&#9744;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by
Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note:</B> Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1) only permits the submission in paper of a Form <FONT
STYLE="white-space:nowrap">6-K</FONT> if submitted solely to provide an attached annual report to security holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check
mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note:</B> Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7) only permits the submission in paper of a Form <FONT
STYLE="white-space:nowrap">6-K</FONT> if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or
legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other document is not a press release, is not required
to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form <FONT STYLE="white-space:nowrap">6-K</FONT> submission or other Commission filing on EDGAR.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the
information to the Commission pursuant to Rule <FONT STYLE="white-space:nowrap">12g3-2(b)</FONT> under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&#9744;&#8195;&#8195;&#8195;No&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule
<FONT STYLE="white-space:nowrap">12g3-2(b):</FONT> <FONT STYLE="white-space:nowrap">82-______________.</FONT> </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>THERATECHNOLOGIES INC. </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d868442dex991.htm">Material Change Report dated September&nbsp;25, 2024 </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">THERATECHNOLOGIES INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Jocelyn Lafond</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Jocelyn Lafond</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">General Counsel and Corporate Secretary</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: September&nbsp;25, 2024 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d868442dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>MATERIAL CHANGE REPORT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT STYLE="white-space:nowrap">51-102F3</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><B>ITEM&#8201;1 - NAME AND ADDRESS OF COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">THERATECHNOLOGIES INC. (&#147;<B>Theratechnologies</B>&#148;, &#147;<B>we</B>&#148; or the &#147;<B>Company</B>&#148;) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">2015 Peel Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">11<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">Montr&eacute;al, Qu&eacute;bec </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">Canada H3A 1T8 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><B>ITEM&#8201;2
- DATE OF MATERIAL CHANGE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">September&nbsp;17, 2024 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><B>ITEM&#8201;3 - NEWS RELEASE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">A news release describing this material change was issued by the Company on September&nbsp;17, 2024 via &#147;GLOBE
NEWSWIRE&#148;. A copy of the news release is available on the SEDAR+ website at <FONT STYLE="font-family:Times New Roman; font-size:11pt" COLOR="#0000ff"><U>www.sedarplus.ca</U></FONT><FONT STYLE="font-family:Times New Roman"> and on the EDGAR
website at <U>www.sec.gov/edgar</U> as an attachment to a Form <FONT STYLE="white-space:nowrap">6-K</FONT> dated September&nbsp;18, 2024. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><B>ITEM&#8201;4 - SUMMARY OF MATERIAL CHANGE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">On September&nbsp;17, 2024, the Company announced a risk of a temporary supply disruption for <I>EGRIFTA SV</I><SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (tesamorelin for injection) in early 2025 caused by an unexpected voluntary shutdown of the Company&#146;s contract manufacturer&#146;s facility following an inspection by the US Food and Drug
Administration (&#147;FDA&#148;), as well as the FDA review timeline to resume distribution of the product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><B>ITEM&#8201;5&#8201;- FULL DESCRIPTION OF
MATERIAL CHANGE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">On September&nbsp;17, 2024, the Company announced a risk of a temporary supply disruption for
<I>EGRIFTA SV</I><SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (tesamorelin for injection) in early 2025 caused by an unexpected voluntary shutdown of the Company&#146;s contract manufacturer&#146;s facility following an inspection by
the FDA, as well as the FDA review timeline to resume distribution of the product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">The Company indicated that it would
continue working with its manufacturer and other stakeholders and would continue to work with the FDA to resume production of <I>EGRIFTA SV</I><SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>. The Company is confident that it will avoid
impact on any patients in 2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">The Company will implement measures to carefully manage the inventory levels of
<I>EGRIFTA SV</I><I><SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP></I> to meet patient demand until early January 2025, and estimates that these measures will result in a shortfall of approximately US$1.6&nbsp;million in revenue from
<I>EGRIFTA SV</I><SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> for its fiscal year 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">Background: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">Theratechnologies&#146;manufacturer of <I>EGRIFTA SV</I><SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> recently
implemented a three-month voluntary shutdown of its facility to address observations by the FDA Office of Compliance, following a plant inspection. The observations issued by the FDA are not related to the
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">- 2 - </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">
manufacturing process of <I>EGRIFTA SV</I><SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, but rather related to the manufacturing environment of the facility. The manufacturer is
finalizing its remediation measures and has confirmed to the Company that it plans to resume activities by <FONT STYLE="white-space:nowrap">mid-October.</FONT> Based on these timelines<I>,</I> a batch of <I>EGRIFTA SV</I><I><SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP></I> is currently scheduled to be manufactured on October&nbsp;21, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">In order to resume distribution of <I>EGRIFTA SV</I><I><SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP></I>,
Theratechnologies was requested by the FDA to file a Prior Approval Supplement (&#147;PAS&#148;) describing the changes made by its manufacturer. The Company expects to file the PAS on or around the manufacturing date. A PAS is reviewed by the FDA
within four months of receipt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">The Company will update the market on any further material developments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:Times New Roman" ALIGN="justify"><B>Forward-Looking Information </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">This material change report contains forward-looking statements and forward-looking information (collectively, the
&#147;Forward-Looking Statements&#148;) within the meaning of applicable securities laws, that are based on management&#146;s beliefs and assumptions and on information currently available to it. You can identify forward-looking statements by terms
such as &#147;may&#148;, &#147;will&#148;, &#147;should&#148;, &#147;could&#148;, &#147;promising&#148;, &#147;would&#148;, &#147;outlook&#148;, &#147;believe&#148;, &#147;plan&#148;, &#147;envisage&#148;, &#147;anticipate&#148;, &#147;expect&#148;
and &#147;estimate&#148;, or the negatives of these terms, or variations of them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">The Forward-Looking Statements
contained in this material change report include, but are not limited to, statements regarding: (i)&nbsp;the time period related to the availability of <I>EGRIFTA SV</I><I><SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP></I> to patients;
(ii)&nbsp;the effectiveness of the measures to be implemented by the Company to manage the inventory level of <I>EGRIFTA SV</I><I><SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP></I>; (iii)&nbsp;the dates on which the Company&#146;s
manufacturer will resume its manufacturing activities and the manufacture of a new batch of <I>EGRIFTA SV</I><I><SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP></I>; and (iv)&nbsp;the monetary impact on the Company&#146;s revenue for the
fiscal year 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">Although the Forward-Looking Statements contained in this material change report are based upon what
the Company believes are reasonable assumptions in light of the information currently available, investors are cautioned against placing undue reliance on these statements since actual results may vary from the Forward-Looking Statements contained
in this material change report. Certain assumptions made in preparing the Forward-Looking Statements include that: (i)&nbsp;the FDA will be satisfied with the remediation measures implemented by the manufacturer in response to the observations
issued by the FDA and the manufacturer will resume its activities by <FONT STYLE="white-space:nowrap">mid-October</FONT> and will manufacture a new batch of <I>EGRIFTA SV</I><I><SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP></I> on
October&nbsp;21, 2024; (ii) no delay in the implementation of the remaining remediation measures at the manufacturer&#146;s site will occur; (iii)&nbsp;the information allowing the Company to file a PAS will be available to the Company prior to
October&nbsp;21, 2024; (iv) the new batch of <I>EGRIFTA SV</I><I><SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP></I> to be manufactured will meet the specifications for market release; (v)&nbsp;the FDA will approve the PAS as filed by the
Company; (vi)&nbsp;current market demand for <I>EGRIFTA SV</I><I><SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP></I> will remain unaffected; and (vii)&nbsp;the financial impact assessment made by the Company about the potential revenue
shortfall from <I>EGRIFTA SV</I><I><SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP></I> is accurate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">Forward-Looking Statements assumptions are subject to a number of risks and uncertainties, many of which are beyond the
Company&#146;s control, that could cause actual results to differ materially from those that are disclosed in or implied by such Forward-Looking Statements. These risks and uncertainties include, but are not limited to: (i)&nbsp;the issuance of
additional observations by the FDA to the manufacturer following the finalization of their review of the remediation measures implemented at the manufacturer&#146;s site; (ii)&nbsp;a delay by the manufacturer in
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">- 3 - </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">
implementing the final remediation measures at the manufacturer&#146;s site; (iii)&nbsp;the receipt of negative results from the implemented remediation measures; (iv)&nbsp;a delay in providing
the information from the remediation measures to the Company; (v)&nbsp;a delay by the Company in filing the PAS; (vi)&nbsp;a decrease in demand for <I>EGRIFTA SV</I><I><SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP></I> due to the risk of
shortage; (vii)&nbsp;the failure of the new batch of <I>EGRIFTA SV</I><I><SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP></I> to meet the specifications allowing its release to the market; and (viii)&nbsp;the FDA <FONT
STYLE="white-space:nowrap">non-approval</FONT> of the PAS to be filed by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">The Company refers current and
potential investors to the &#147;Risk Factors&#148; section of the Company&#146;s Form <FONT STYLE="white-space:nowrap">20-F</FONT> dated February&nbsp;21, 2024 available on SEDAR+ at <FONT
STYLE="font-family:Times New Roman; font-size:11pt" COLOR="#0000ff"><U>www.sedarplus.ca</U></FONT><FONT STYLE="font-family:Times New Roman"> and on EDGAR at
</FONT><FONT STYLE="font-family:Times New Roman; font-size:11pt" COLOR="#0000ff"><U>www.sec.gov</U></FONT><FONT STYLE="font-family:Times New Roman"><U> </U>under Theratechnologies&#146; public filings. The reader is cautioned to consider these and
other risks and uncertainties carefully and not to put undue reliance on forward-looking statements. Forward-Looking Statements reflect current expectations regarding future events and speak only as of the date of this material change report and
represent the Company&#146;s expectations as of that date. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">The Company undertakes no obligation to update or
revise the information contained in this material change report, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><B>ITEM&#8201;6 - RELIANCE ON SUBSECTION 7.1(2) OR (3)&nbsp;OF NATIONAL INSTRUMENT <FONT STYLE="white-space:nowrap">51-102</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">Not applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><B>ITEM&#8201;7 - OMITTED INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">Not applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><B>ITEM&#8201;8 - EXECUTIVE OFFICER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">For further information, contact Jocelyn Lafond, General Counsel and Corporate Secretary of the Company at (438) <FONT
STYLE="white-space:nowrap">315-6607.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><B>ITEM&#8201;9 - DATE OF REPORT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">September&nbsp;25, 2024. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
